LTX-002

DRUG2 trials

Sponsors

Leal Therapeutics Inc., Leal Therapeutics, Inc

Conditions

Amyotrophic Lateral Sclerosis

Phase 1

A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis

Not yet recruitingCTIS2025-522039-33-00

Leal Therapeutics Inc.Amyotrophic Lateral Sclerosis

Target: 5Updated: 2026-01-23

A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis

RecruitingNCT07660614

Leal Therapeutics, IncAmyotrophic Lateral Sclerosis

Start: 2026-04-29End: 2031-06-01Target: 56Updated: 2026-08-18